Literature DB >> 28180104

Late Migration of Amplatzer Septal Occluder Device to the Descending Thoracic Aorta.

Hyo-Hyun Kim1, Gi-Jong Yi1, Suk-Won Song1.   

Abstract

Percutaneous closure of atrial septal defect (ASD) has become an increasingly common procedure. Serious complications of the procedure, such as cardiac migration, are rare, and usually occur <72 hours after device placement. In this report, we present the case of a patient who underwent successful surgical treatment for the migration of an ASD occluder device to the thoracic aorta 12 months after ASD closure.

Entities:  

Keywords:  Atrial heart septal defect; Bilateral thoracotomy; Foreign-body migration; Septal occluder device; Thoracic aorta

Year:  2017        PMID: 28180104      PMCID: PMC5295484          DOI: 10.5090/kjtcs.2017.50.1.47

Source DB:  PubMed          Journal:  Korean J Thorac Cardiovasc Surg        ISSN: 2233-601X


Case report

Atrial septal defect (ASD) is the fourth most common congenital heart defect, with an incidence of 2.78 per 10,000 live births [1]. Surgical closure of ASD has been practiced for more than 45 years and is considered the method of choice. The first application of ASD closure in humans was in 1974, by Lock [2], and the technique was pioneered by William. Recently, a variety of devices for transcatheter closure of ASD have become available, and this technique is increasingly used as an alternative to open surgery [3,4]. The rate of failure, including dislodgement, migration, or embolization, has been reported to be around 0.5% [5]. In this report, we present the case of a patient who underwent successful surgical treatment for the migration of an ASD occluder device to the descending aorta 12 months after ASD closure. A 65-year-old man was admitted to the cardiology clinic at Gangnam Severance Hospital with progressively limiting exertional dyspnea. He had an ASD secundum, which had been diagnosed 10 years earlier. Echocardiography on admission showed a 2.3×1.7-cm, oval-shaped ASD. The patient underwent transcatheter closure using a 24-mm Amplatzer septal occluder (AGA Medical Co., Golden Valley, MN, USA) guided by transesophageal echocardiography (TEE). Conventional chest radiography was performed every morning after implantation. The patient was discharged after 3 days of hospitalization. The proper position of the device was confirmed by transthoracic echocardiography (TTE) on the day of discharge. There were no immediate postoperative complications. The patient underwent clinical examination, electrocardiography, chest radiography, and TTE at 1 month and 6 months after ASD closure. At a routine follow-up visit, a year after implantation, the diagnosis of device migration was made based on a chest computed tomography (CT) scan and echocardiography (Fig. 1). The chest CT scan showed the presence of the ASD occluder device in the descending thoracic aorta at the level of T6–T7. TEE showed no interruption in aortic blood flow between the device and the aortic lumen. The patient had no symptoms, such as chest discomfort or dyspnea, associated with ASD occluder migration. Physical examination revealed no abnormal findings. Because of the risk of aortic plugging or perforation, the patient was referred to the operating room.
Fig. 1

(A, B) Chest computed tomography scan showing the migrated Amplatzer occluder device.

With the patient in the supine position, clamshell incisions were made bilaterally into the fifth inter-costal space, and the pericardium was incised vertically. Following standard bicaval cannulation and aortic cross-clamping, antegrade blood cardioplegia was introduced. Patch repair of ASD was carried out using a bovine pericardial patch. During the rewarming period, the descending thoracic aorta was cross-clamped at the level of T5 (proximally) and T8 (distally), and was opened longitudinally. The device was removed through the incision after adhesiolysis (Fig. 2). The aortic wall was closed using a primary simple suture. Pathological examination of the retrieved specimen showed that structural integrity of the device was maintained without distortion (Fig. 2).
Fig. 2

(A) Photograph taken during surgery showing the tear into the aorta caused by the edge of the Amplatzer device, and (B) an en face view of the device.

The aortic cross-clamp (ACC) time for the removal of the ASD device was 9 minutes, and the total operation time was 116 minutes with an ACC time of 43 minutes. The patient stayed in the intensive care unit for 36 hours postoperatively. There were no peri-operative or postoperative complications.

Discussion

Until recently, open surgical repair of ASD has been the only available treatment [1]. A number of different devices are available for transcatheter ASD closure, with the Amplatzer device being the first choice for closing defects of secundum ASD larger than 18 mm [4]. The overall incidence of complications of transcatheter ASD closure has been reported to range from 6.1% to 11.1%, with embolization and malposition being the most common (3.5%), accounting for half of the complications during hospitalization. Embolization occurs with 24-mm or larger devices, while malposition occurs with 19-mm and 22-mm devices [1]. The dislocated device can migrate to the main pulmonary artery [1,5], left ventricle, left atrium [6], ascending aorta [6], aortic arch [4], or descending thoracic aorta. Devices usually embolize into the main pulmonary artery (89%). Most migrations (67%) are detected within the first 24 hours [5], and migration to the descending thoracic aorta in the late postoperative period (>1 year) is an extremely rare occurrence. This case was remarkable for the fact that migration occurred a few months after implantation, highlighting the need for careful follow-up, particularly when the rim of the ASD is insufficient. Divekar et al. [6] reviewed all the 29 reported complications of Amplatzer septal occluder devices and found that embolization tended to occur when the aortic rim was insufficient. In our case, it appeared that the posterior rim of the atrial septum was very thin and highly mobile. Classically, median sternotomy provides exposure to the anterior and middle mediastinum, and it is ideal for access to the heart and innominate vessels. However, the descending thoracic aorta and posterior aspect of the aortic arch are inaccessible through this approach. Bilateral anterior thoracotomies (clamshell) allow access to all aspects of the thoracic aorta, both pulmonary vessels, superior vena cava, inferior vena cava, both atria, and both ventricles [7]. Furthermore, this approach allows for easy extension to the neck and abdomen if further control is required [8]. Therefore, a clamshell incision was chosen for ASD device removal and ASD repair. To the best of our knowledge, this is the first reported case of the late migration of an occluder device to the descending thoracic aorta, and the only reported use of a clamshell incision for ASD device removal and ASD repair.
  8 in total

1.  Secundum atrial septal defect. Nonoperative closure during cardiac catheterization.

Authors:  T D King; S L Thompson; C Steiner; N L Mills
Journal:  JAMA       Date:  1976-06-07       Impact factor: 56.272

2.  Bilateral anterior thoracotomy (clamshell incision) is the ideal emergency thoracotomy incision: an anatomic study.

Authors:  Eric R Simms; Alexandros N Flaris; Xavier Franchino; Michael S Thomas; Jean-Louis Caillot; Eric J Voiglio
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

3.  Closure of atrial septal defects with the Amplatzer occlusion device: preliminary results.

Authors:  B D Thanopoulos; C V Laskari; G S Tsaousis; A Zarayelyan; A Vekiou; G S Papadopoulos
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

Review 4.  Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder.

Authors:  Abhay Divekar; Tidimogo Gaamangwe; Nasir Shaikh; Michael Raabe; John Ducas
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

5.  Early and late complications associated with transcatheter occlusion of secundum atrial septal defect.

Authors:  Massimo Chessa; Mario Carminati; Gianfranco Butera; Roberta Margherita Bini; Manuela Drago; Luca Rosti; Alessandro Giamberti; Giuseppe Pomè; Eduardo Bossone; Alessandro Frigiola
Journal:  J Am Coll Cardiol       Date:  2002-03-20       Impact factor: 24.094

6.  Surgical revision of an uncommonly dislocated self-expanding Amplatzer septal occluder device.

Authors:  Nikolaos B Tsilimingas; Beate Reiter; Yskert V Kodolitsch; Thomas Münzel; Thomas Meinertz; Thomas Hofmann
Journal:  Ann Thorac Surg       Date:  2004-08       Impact factor: 4.330

7.  Penetrating thoracic trauma.

Authors:  Renata Bastos; Clinton E Baisden; Lori Harker; John H Calhoon
Journal:  Semin Thorac Cardiovasc Surg       Date:  2008

8.  Emergency surgical approach to device emboli due to migration of the atrial septal defect occluder.

Authors:  Ufuk Yetkin; Ismail Yurekli; Zehra Ilke Akyildiz; Orhan Gokalp; Omer Tetik; Banu Lafci; Oktay Ergene; Ali Gurbuz
Journal:  Arch Med Sci       Date:  2014-06-27       Impact factor: 3.318

  8 in total
  4 in total

1.  Late presenting partially displaced atrial septal closure device: Surgical vs percutaneous correction? A case report.

Authors:  Mian Mustafa Kamal; Abdul Ahad Sohail; Mian Yasir Kamal; Naveed A Pasha; Syed Shahabuddin; Hasanat Sharif
Journal:  Int J Surg Case Rep       Date:  2022-09-09

2.  Surgical Removal of Migrated Atrial Septal Defect Closure Device: A Case Report.

Authors:  Sunjoo Kim; Sangil Min
Journal:  Vasc Specialist Int       Date:  2022-09-29

3.  Conservative management of asymptomatic lately embolized amplatzer atrial septal occluder device to the supraceliac abdominal aorta: case report and the literature review.

Authors:  Samer Koussayer; Ahmed Mousa; Mai A Elkalla; Raghad Alaujan; Bassam Khalil
Journal:  Radiol Case Rep       Date:  2021-05-26

4.  A unique late complication of transcatheter atrial septal defect closure.

Authors:  Gökhan Altunbaş; Mehmet Adnan Celkan; Ertan Vuruşkan; Murat Sucu
Journal:  Anatol J Cardiol       Date:  2019-11       Impact factor: 1.596

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.